Processa Pharmaceuticals, Inc. — Director's Dealing 2025

Oct 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2025-10-01

Reporting Person: Pannu Geraldine (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-01	Restricted Stock Units	$0	A	100000	Acquired		Common Stock (100000)	Direct
2025-10-01	Stock Options (Right to Buy)	$0.198	A	300000	Acquired		Common Stock (300000)	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.

F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.